Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous
How this was made
The 30-second read
Why it matters
Traders can update expectations for near-term trial execution (active sites, enrollment pace) and balance-sheet risk (cash runway), while monitoring the next planned clinical data update in Q4 2026.
Market read
The combination of higher cash, faster trial enrollment, and a defined next data window can reprice probability-weighted outcomes for APR-1051.
What to watch
The filing increases R&D expense versus prior year and does not provide new efficacy magnitude beyond “early signs,” so valuation may remain sensitive to future dose-limiting toxicity and response durability.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and an operational update for Aprea’s lead programs APR-1051 (WEE1 inhibitor) and ATRN-119 (ATR inhibitor).
Ticker impact
Aprea’s 8-K reports Q2 2026 cash of $41.2M and accelerates enrollment and dose escalation in its ACESOT-1051 APR-1051 Phase 1 trial.
Likely supportive for sentiment, with upside skew if investors view the accelerated enrollment and upcoming Q4 2026 data as de-risking.
New primary disclosures include cash runway through Q1 2028, active-site expansion from 3 to 10, and a stated expectation to reach 6 to 10 patients per month by Q4 2026, plus planned expansion into additional biomarker-defined cohorts and combination settings.
Market effects
Adds incremental signal for WEE1/DDR-targeted oncology development timelines and trial execution risk in small-cap precision oncology.
No clear regional spillover beyond US small-cap biotech sentiment.
Limited global impact; primarily affects investors tracking early-stage oncology pipelines.
Counterpoint
Accelerating enrollment does not guarantee improved efficacy or tolerability; early Phase 1 signals can still fail in later cohorts or combinations.
Key entities
- companyAprea Therapeutics, Inc.
Clinical-stage precision oncology company; subject of the 8-K with Q2 2026 results and APR-1051 trial updates.
- drug_programAPR-1051
Oral WEE1 inhibitor in the ACESOT-1051 Phase 1 dose-escalation study; enrollment and dose escalation are being accelerated.
- clinical_trialACESOT-1051
Multi-center, open-label Phase 1 trial; active sites expanding from 3 to 10 and enrollment expected to reach 6 to 10 patients per month by Q4 2026.
- drug_programATRN-119
Macrocyclic ATR inhibitor; ABOYA-119 Phase 1/2a dose escalation closed, with potential combination discussions ongoing.
